News and Trends 21 Mar 2017 A Potential First Treatment for a Rare Genetic Disease clears Phase I Minoryx Therapeutics has successfully completed a Phase I trial for its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD). The Spanish biotech Minoryx is specialized on orphan diseases and its lead program is a PPAR-gamma agonist, MIN-102, which is in development for X-ALD. The company now announced the successful results of its Phase I trial with MIN-102 revealing the […] March 21, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2017 Will BMS Take Over a Danish Biotech in a Massive €400M Deal? Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option of take over the biotech. In 2014, Denmark’s Galecto Biotech has signed an option agreement with US-based pharma Bristol-Myers Squibb (BMS) for its lead asset TD139, which is under development for the treatment of pulmonary […] March 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2017 French Biotech fails Second Phase II Trial for Cardiovascular Disease Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment of cardiovascular and metabolic diseases. The company now presented data on its lead candidate CER-001, which was investigated in a Phase II study for the treatment of patients with post-acute […] March 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 18 Mar 2017 Wellcome Image Awards: These are the Best Biology Images of the Year The UK’s Wellcome trust has selected 22 pictures and images that capture the wonders of the life sciences. They’re now on exhibition in the UK and Ireland. The Wellcome Image Awards celebrates this year 20 years of bringing us the best biology images around the world. The awards are destined to visual masterpieces that communicate key aspects […] March 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2017 Can this British Biotech Overcome Failure buying drugs from AstraZeneca? After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to acquire rights from two AstraZeneca products for pulmonary disease. Circassia could not beat the placebo in a Phase III trial for cat allergy last year, which immediately drove its stock down by 65% and led to the halt of clinical […] March 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Mar 2017 This French Startup is Paving the way for Bioplastics from Milk Can we make plastics out of milk byproducts? The startup Lactips, based near Lyon, is getting ready to make this special kind of bioplastic a commercial reality with its first application, wrapping for detergents. Pun intended: Lactips’ motto is “the milky way of plastics,” and that’s what the startup has been developing since its foundation in […] March 17, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2017 Researchers Develop New Virus to Selectively Attack Tumor Cells Researchers from Barcelona have developed a new genetically engineered oncolytic virus, which can selectively infect and kill tumor cells. Eneko Villanueva and colleagues from the IDIBAPS Biomedical Research Institute and the Institute for Research in Biomedicine (IRB Barcelona) have engineered a virus that infects tumor cells without affecting healthy tissues. Their new cancer therapy approach is based […] March 16, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2017 UK Immunotherapy Biotech raises Massive Funding in Series C The UK biotech Cell Medica picked up a massive €69M (£60M) in its recent Series C funding round to advance its cancer immunotherapy programs. Cell Medica is a clinical stage company developing cell-based therapies to treat cancer. With the aim of advancing the clinical development of its immunotherapies, the company was able to raise an impressive […] March 16, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2017 What’s Berlin’s Secret to Success in Biotech & Digital Health? Berlin is a creative crossroads not just for arts but also life science. A variety of players in academia, industry, and startups make the ecosystem blossom. To those who know Berlin as a creative hub, it might come as a surprise that life science is one of the city’s industrial pillars. The German capital region […] March 16, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2017 France Closes in on an HIV Cure by Detecting Cells with Dormant Viruses French researchers have found a protein only expressed in HIV-infected reservoir cells, paving the way for an HIV cure that completely eliminates the virus. Researchers from the Institut de Génétique Humaine (IGH) at Montpellier University, France, have discovered a protein, CD32a, that is only present on the surface of CD4 T cells infected with dormant HIV. This […] March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2017 Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development alliance with the American Editas Medicine, which is on the side of […] March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2017 Huge Successful €103M IPO for the Next European Leader in Bioplastics Avantium has gone public and raised €103M on Euronext Amsterdam and Euronext Bruxelles with Sofinnova Partner as the main shareholder. Avantium, a spin-off from Shell, is developing renewable bioplastics made 100% from plant-based materials with the support of big partners such as Coca-Cola or Danone, for which the Dutch biotech is developing sustainable PlantBottles and yogurt cups, […] March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email